Molecular Pharmacology Program

The Hedvig Hricak Lab

Research

Hedvig Hricak, MD, PhD

Chair, Department of Radiology

Professor

Our laboratory is working on establishing phenotypic signatures of cancer using multimodality anatomic and molecular imaging. We also aim to integrate multimodality imaging with anatomic pathology, genomics, and other molecular signatures to gain further insight into comprehensive molecular and anatomic tumor profiling. The goal is to further advance understanding of in vivo tumor biology and tumor heterogeneity (both spacial and temporal). We plan to develop and validate tumor biomarkers that can be used for treatment selection, assessment of treatment response or early detection of treatment resistance. Using advanced computational methods of radiomics and radiogenomics, we are evaluating how multimodality/multiplexing technology can advance our knowledge of tumor phenotypes and their associations with genomic mutations. We are also exploring targeted imaging and targeted therapies to ultimately expand the field of theranostics, which we believe is one of the future paths to precision medicine.

View Lab Overview

Featured News

In the Clinic

How Our New Particle Accelerator Will Make Cancer Imaging and Treatment More Precise

Friday, June 27, 2014

Announcement

Memorial Sloan Kettering Launches New Center for Molecular Imaging and Nanotechnology

Monday, May 12, 2014

New Nanotechnology Center Combines Cutting-Edge Science with Memorial Sloan Kettering's Expertise in Patient Care

Saturday, January 1, 2011

View All Featured News

Publications

Vargas HA, Wassberg C, Fox JJ, Wibmer A, Goldman DA, Kuk D, Gonen M, Larson SM, Morris MJ, Scher HI, Hricak H. Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology. 2014 Apr;271(1):220-9. PubMed Central PMCID: PMC4263648. PubMed

Donati OF, Afaq A, Vargas HA, Mazaheri Y, Zheng J, Moskowitz CS, Hricak H, Akin O. Prostate MRI: evaluating tumor volume and apparent diffusion coefficient as surrogate biomarkers for predicting tumor Gleason score. Clin Cancer Res. 2014 Jul 15;20(14):3705-11. PubMed

Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Mironov S, Iyer RB, Zhou Q, Iasonos A, Paul H, Hosaka M, Aghajanian CA, Leitao MM Jr, Gardner GJ, Abu-Rustum NR, Sonoda Y, Levine DA, Hricak H, Chi DS. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol. 2014 Sep;134(3):455-61. PubMed Central PMCID: PMC4387777. PubMed

Donati OF, Mazaheri Y, Afaq A, Vargas HA, Zheng J, Moskowitz CS, Hricak H, Akin O. Prostate cancer aggressiveness: assessment with whole-lesion histogram analysis of the apparent diffusion coefficient. Radiology. 2014 Apr;271(1):143-52. PubMed

Wibmer A, Hricak H, Gondo T, Matsumoto K, Veeraraghavan H, Fehr D, Zheng J, Goldman D, Moskowitz C, Fine SW, Reuter VE, Eastham J, Sala E, Vargas HA. Haralick texture analysis of prostate MRI: utility for differentiating non-cancerous prostate from prostate cancer and differentiating prostate cancers with different Gleason scores. Eur Radiol. 2015 Oct;25(10):2840-50. PubMed Central PMCID: PMC5026307. PubMed

View All Publications

People

Hedvig Hricak, MD, PhD

Chair, Department of Radiology

Professor

Radiologist Hedvig Hricak researches methodologies of molecular imaging of prostate and gynecologic tumors.
MD, University of Zagreb School of Medicine (Yugoslavia)
Dr. Med. Sc. Karolinska Institute (Sweden)